Oasmia Pharmaceutical AB
21.10.2014 08:30
Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Submission for European marketing approval of Paclical in 2015
Uppsala, Sweden, 2014-10-21 08:30 CEST (GLOBE NEWSWIRE) --
UPPSALA, SWEDEN - October 21, 2014. Oasmia Pharmaceutical AB (publ) today announced
that the full clinical trial report of Paclical, for the treatment of
epithelial ovarian cancer, shows a positive risk/benefit profile. The data will
serve as the basis of a Marketing Authorisation Application to the European
Medicines Agency (EMA), which the company intends to submit in early
2015.
'Shorter infusion time and no need for pre-medication with
corticosteroids or antihistamines give Paclical an advantage over paclitaxel
(Taxol(R))', said Professor Ignace Vergote, principal investigator of the study
and Chairman of the Leuven Cancer Institute, University Hospitals Leuven,
Leuven, Belgium
The primary objective of the Phase III clinical study, which
included in total 789 patients, was to show non-inferiority of Paclical (250
mg/m2) versus Taxol (175 mg/m2), both in combination with carboplatin. Tumour
response and progression was assessed using computed tomography (CT) evaluated
centrally according to Response Evaluation Criteria in Solid Tumors (RECIST).
The initial data of the study, presented on June 16, 2014, showed
that Paclical, which has orphan designation for epithelial ovarian cancer in
the EU and in the US, met the pre-defined requirement of non-inferiority
compared with Taxol.
Oasmia has now completed a full analysis of the study data,
including a comprehensive risk/benefit evaluation, which shows a positive
risk/benefit profile for Paclical.
'The conclusion after examining all data in the study is that the
benefit with Paclical treatment exceeds the risks with the treatment. The data
will serve as the basis of a Marketing Authorisation Application to the
European Medicines Agency (EMA), which we intend to submit in the second
quarter of 2015', commented Julian Aleksov, CEO of Oasmia.
The risk/benefit analysis is based on data from the study,
including:
- The percentage of patients with a substantial decrease
in tumour burden - including normalized levels of the biomarker used for this
evaluation - is 86% for patients treated with Paclical and 85% for patients
treated with paclitaxel (Taxol). The percentage of those with normalized
biomarker levels (=complete response) is 62% for both treatments. This implies
that Paclical is an effective treatment of ovarian cancer when used in
combination with carboplatin.
- Time of progression free survival is 10.2 months compared to Taxol
(10.0 months) and is in line with what has previously been published for
patients after the first or second relapses. More frequent CTs (every 3 months)
were done in a substantial subgroup of 243 patients. The median PFS time in
this subgroup was 12.2 months for Paclical and 10.2 for paclitaxel
(Taxol).
- The intended infusion time
for Paclical is 1 hour, compared to Taxol's 3-hour infusion time, and only on
rare occasions were there any prolongation of the infusion time.
- Corticosteroids and antihistamines are not indicated as
pre-treatment
before Paclical, which was confirmed in this study, as only a limited number of
patients received such medication before treatment with Paclical.
- The overall safety profile of Paclical is in line with
what was expected for paclitaxel. However, a dose-dependent increase in
frequency and severity of adverse events was not seen, apart from those related
to the white blood cells. This means that despite the higher dose compared to
Taxol, adverse events related to paclitaxel are not more common with
Paclical.
- Neuropathy (numbness of hands
and feet) is an adverse event related to treatment with paclitaxel. Neuropathy
is also seen with Paclical, but to a somewhat lesser degree than with Taxol,
despite the higher Paclical dose.
- Despite the adverse events reported, including frequent blood cell
related adverse events, the dose was reduced in only 18% of the patients.
Dose-reduction below 200 mg/m2 was rare. The investigators did thus not reduce
the dose of Paclical to the level of Taxol (175 mg/m2).
All data examined shows a consistent although not
significant advantage of Paclical in all efficacy variables compared with
Taxol. The safety profile was similar with an expected increase in frequency
and severity of white blood cell related events and a non-expected decrease in
neuropathy. Dose reduction to the level of Taxol (175 mg/m2) was rare although
allowed according to the protocol.
'The study shows that Paclical is at least as good as paclitaxel
(Taxol) in providing time without progression in patients with ovarian cancer,
and Paclical gives the patients the advantage of a shorter infusion time and
allergic reactions are very rare compared to paclitaxel (Taxol). I am really
happy with the results and to have participated in this study', commented
Professor Vergote.
Oasmia now intends to submit a Marketing Authorisation Application
to EMA in Q2 2015.
Overall survival data are expected in Q3 2015.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical
AB develops new generations of drugs in the field of human and veterinary
oncology. The company's product development aims to create and manufacture novel
nanoparticle formulations and drug-delivery systems based on well-established
cytostatics, which, in comparison with current alternatives, show improved
properties, reduced side effects, and expanded applications. The
company's
product development is based on its proprietary in-house research and company
patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt
Stock Exchange (OMAX, ISIN SE0000722365). www.oasmia.com
About the Phase III clinical study of Paclical
The Phase III open,
randomized, multi-centre study, which included in total 789 patients, was
designed to compare the efficacy and safety between Paclical and Taxol, which
is also a paclitaxel-based product. Both Paclical and Taxol were administered
in combination with carboplatin.
Paclitaxel in combination with carboplatin, or any other platinum
containing compound, has emerged as a standard in a first line setting in
patients with epithelial ovarian cancer, and is used also as second line
treatment, providing the patient had a response time of at least 6 months.
These patients are defined as platinum sensitive.
The period from randomization to relapse or death (PFS) becomes
shorter with the number of relapses, and hence treatment periods, that the
patient goes through. A study comparing the period of the first PFS with the
second showed a difference of 7 months, 17.8 compared to 10.8 months.
The study showed a PFS period of 10.3 months for Paclical +
carboplatin compared to 10.1 months for Taxol + carboplatin. The result
corresponds well with literature data from studies in platinum sensitive
patients in second line treatment, e.g. 10.8 months (ref 1) and 9.4
months.
The study was designed to achieve the following primary
objective:
PFS: to show non-inferiority of Paclical (250 mg/m2) vs Taxol (175
mg/m2, using computed tomography (CT) scans according to Response Evaluation
Criteria in Solid Tumors (RECIST), as assessed by central review.
Inclusion criteria included patients who relapsed at least six
months after end of first line or second line treatment including platinum
based therapy. Paclical was administered as a one-hour intravenous infusion at
its recommended dose of 250 mg/m2. Taxol was administered as a three-hour
intravenous infusion at its recommended dose of 175 mg/m2. Both drugs were
dosed in six three-week cycles.
Patients treated with Taxol received systemic pre-treatment with
corticosteroids, antihistamines and H2 receptor antagonists. Patients treated
with Paclical did not receive such treatment to the same extent Carboplatin was
given as an intravenous infusion starting 30 minutes after the end of the
paclitaxel infusion. The carboplatin dose is based on kidney function measured
as creatinine clearance ('5-6 AUC')
that means that the variation in dose between patients is large, with a mean of
approximately 625 mg/cycle, but it can be twice that much for an individual
patient. After completing the treatment cycles, patients were followed until
progression.
About Paclical
Paclical is a
water-soluble formulation of the well-known cytostatic paclitaxel combined with
Oasmia's
excipient technology XR-17. Paclitaxel is one of the most widely used
anticancer substances and is included in the standard treatment of a variety of
cancers such as lung cancer, breast cancer and ovarian cancer. Paclical
consists of a freeze-dried powder dissolved in conventional solution for
infusion. It has orphan drug designation in the EU and the US.
About the Paclical market
The two leading
paclitaxel-based products on the market are Taxol and Abraxane, two widely used
cancer drugs. Taxol generated $1.6 billion in sales in 2000 alone, prior to
losing its patent protection in 2001. In 2013, Taxol generated $92 million in
post-patent sales. Abraxane, which received FDA approval in 2005 for metastatic
breast cancer, followed by approvals for lung (in 2012) and pancreatic cancer
(in 2013), generated $427 million in worldwide annual sales in 2012 and
generated $649 million in 2013.
In order to deliver paclitaxel, Taxol contains the solvent
Cremophor EL. The toxicity of Cremophor EL limits the dose of Taxol that can be
administered during a reasonable time, potentially limiting the efficacy of the
drug. In addition, patients receiving Taxol require premedication with steroids
and antihistamines to prevent the toxic side effects associated with the
combination of paclitaxel and Cremophor EL.
Abraxane was developed as a Cremophor-free product containing
paclitaxel suspended in human albumin. Because Abraxane contains no Cremophor
EL solvent, Abraxane's recommended dosing enables the delivery of 50% more
paclitaxel while maintaining a similar safety profile, and requires no routine
pre-medication to prevent hypersensitivity reactions or the immediate allergic
effects that often prevent or limit treatment. Like Abraxane, Paclical is free
of Cremophor EL, but unlike Abraxane, Paclical does not contain human
albumin.
About XR-17
XR-17 is Oasmia's
proprietary excipient and is based on Vitamin A. It forms micelles that are
between 20 and 60 nanometres in size. One property that makes XR-17 special is
that it can also form micelles with water-soluble substances. This increases
its potential uses significantly. Once XR-17 has delivered the encapsulated
molecule or molecules to the target, the excipient is metabolized naturally.
XR-17 facilitates the ease of administration and allows for higher doses than
some of the other existing pharmaceutical products on the market, including
cytostatics such as paclitaxel.
About epithelial ovarian cancer
Epithelial ovarian
cancers account for about 85% to 90% of ovarian cancers, and are the most
aggressive and dangerous sub-type. According to the National Cancer Institute,
in 2011, the most recent year in which data is available, there were over
185,000 women living with ovarian cancer in the U.S. The five-year survival
rate for ovarian cancer from 2004 to 2010 was 44.6%, and it is estimated that
21,980 women will develop and 14,270 women will die from ovarian cancer in
2014.
In the EU, the five-year survival rate for ovarian cancer was
37.6% from 2000-2007 according to a study published in The Lancet. In 2012,
there were 44,149 diagnosed cases of ovarian cancer in the EU, according to the
European Cancer
Observatory/International Agency for Research on Cancer, while
29,758 women died of ovarian cancer. In the U.S., 51% of women with ovarian
cancer are diagnosed with stage III cancer, characterized by microscopically
confirmed peritoneal metastasis outside the pelvis and/or regional lymph node
metastasis. Common chemotherapy drugs used for the treatment for ovarian cancer
include cisplatin or carboplatin, and paclitaxel or docetaxel, which are most
often given in combination.
About Risk/Benefit analysis
When you do a
risk/benefit analysis, you put together all the factors that can be negative to
the patient (risk), for instance side effects, if a certain medicine is needed
before the treatment, and negative effects of quality of life, with factors
that affect the patient in a positive way (benefit), such as disease free
period, shorter infusion time and positive effects on quality of life, thereby
getting a full overview where the benefit has to be greater than the
risk.
Mikael Widell, Vice President Communications
Mobile: +46 70 311 99 60
E-mail: mikael.widell@oasmia.com
News Source: NASDAQ OMX
21.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Oasmia Pharmaceutical AB
Sweden
Phone:
Fax:
E-mail:
Internet:
ISIN: SE0000722365
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------